Aclaris Therapeutics, Inc. ACRS
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.93% | -8.48% | -0.15% | -35.45% | 5.28% |
| Total Depreciation and Amortization | -6.54% | 4.90% | 0.00% | -7.27% | -3.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.61% | -7.07% | -3.85% | 12.36% | -35.13% |
| Change in Net Operating Assets | -469.25% | 12.55% | -150.22% | 428.76% | -19.37% |
| Cash from Operations | -21.33% | -9.36% | -38.21% | -20.12% | -9.40% |
| Capital Expenditure | 77.59% | -346.15% | 45.83% | -4.35% | -9.52% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -421.72% | 133.38% | -397.50% | -24.98% | 173.34% |
| Cash from Investing | -423.67% | 133.18% | -398.31% | -25.03% | 174.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 51,292.98% | -99.80% | -- | -- | -- |
| Repurchase of Common Stock | -173.91% | 90.80% | -54.32% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 22.08% | -- |
| Cash from Financing | 64,213.19% | -99.84% | 2,380.23% | 16.75% | -33,722.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.93% | -209.11% | 264.27% | -3,527.40% | 97.05% |